Goldman Sachs Group Inc Zynerba Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	BUY	$0.87 - $1.36 $9,869 - $15,427	11,344 New	11,344 $8,000
Q3 2022 Nov 10, 2022	BUY	$0.87 - $1.36 $9,869 - $15,427	11,344 New	11,344 $0
Q2 2022 Aug 15, 2022	SELL	$0.86 - $2.06 $18,684 - $44,755	-21,726 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.83 - $3.02 $12,709 - $20,973	-6,945 Reduced 24.22%	21,726 $45,000
Q4 2021 Feb 14, 2022	SELL	$2.88 - $4.3 $103,095 - $153,927	-35,797 Reduced 55.53%	28,671 $83,000
Q3 2021 Nov 10, 2021	BUY	$3.72 - $5.35 $239,820 - $344,903	64,468 New	64,468 $273,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.